A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

NCT04495296 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: TST001
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Nivolumab

Sponsor

Suzhou Transcenta Therapeutics Co., Ltd.

Collaborators

[object Object]